James Hardie Industries (JHX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Aug, 2026Executive summary
Annual Meeting scheduled for 20 August 2026 (US) and 21 August 2026 (Australia) to address key proposals and shareholder concerns.
Board and leadership engaged extensively with shareholders and proxy advisors after disappointing 2025 voting outcomes, leading to compensation structure redesign.
Board encourages shareholders to vote in favor of all resolutions, emphasizing alignment with shareholder interests and long-term value creation.
Voting matters and shareholder proposals
Proxy advisor Ownership Matters recommended voting against the CEO's Equity Grant (Proposal 4), but acknowledged improvements in the LTI structure.
Board urges support for Proposal 4, citing material changes such as reduced LTI opportunity and removal of the cash-settled Scorecard LTI.
Shareholders are invited to contact Investor Relations for questions on any resolutions or proposals.
Board of directors and corporate governance
Board composition includes directors from the UK, USA, and Australia, with Nigel Stein as Independent Non-Executive Chair.
Board demonstrates responsiveness to shareholder feedback, particularly regarding executive compensation.
Latest events from James Hardie Industries
- Net sales and adjusted EBITDA exceeded guidance, prompting a raised FY27 outlook.JHX
Q1 20277 Aug 2026 - Record Q1 EBITDA and 4% sales growth achieved; FY25 guidance reaffirmed amid market headwinds.JHX
Q1 20258 Jul 2026 - Shareholders will vote on board, pay, auditor, and governance changes after a year of major transformation.JHX
Proxy filing1 Jul 2026 - Director elections, say-on-pay, auditor ratification, and governance amendments up for vote.JHX
Proxy filing1 Jul 2026 - Major acquisition, board refresh, and executive pay overhaul highlight FY26 governance and strategy.JHX
Proxy filing18 Jun 2026 - AZEK acquisition and synergy gains drove strong sales and EBITDA growth, with FY27 targets raised.JHX
Q4 202620 May 2026 - Net sales up 30% to $1.24B, with higher EBITDA and raised FY26 guidance amid synergy progress.JHX
Q3 202613 Apr 2026 - Q2 FY26 sales jumped 34% on AZEK deal; margins fell, but FY26 outlook and synergies improved.JHX
Q2 20263 Feb 2026 - H1 EBITDA topped $500m, FY25 guidance and buybacks raised despite lower sales.JHX
Q2 202514 Jan 2026